Phanes Therapeutics, Inc.

Phanes Therapeutics, Inc. is a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology. Founded in July 2016, the company is led by a team of industry veterans with extensive drug discovery and development experience at global pharma and biotech companies including Pfizer, Amgen, and J&J. Phanes is currently conducting three Phase 2 clinical trials with its lead candidates spevatamig, peluntamig, and mavrostobart. Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug and Fast Track designations by the FDA. The company's mission is to become a major source of innovation in the biopharma industry, combining innovative science, disruptive technologies, and revolutionary approaches to improve outcomes for patients with cancer. Phanes has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair®, and ATACCbody®. These platforms enable the development of novel biologics that address high unmet medical needs in oncology. The PACbody® platform enables construction of native IgG-like bispecific antibodies (PACbodies) with drug-like properties, produced without any protein fusion steps, significantly reducing CMC risks. The SPECpair® platform enhances the manufacturability of bispecific antibodies so that PACbodies can be produced using the conventional mAb manufacturing process. The ATACCbody® platform is an extension of PACbody® and SPECpair®, enabling reversible modulation of the anti-CD3 activity of T cell engagers, designed to target solid tumors with reduced risk of cytokine release syndrome. Phanes Therapeutics is a private company headquartered in the United States, operating globally in the biopharmaceutical sector.

Phanes Therapeutics, Inc. was founded in July 2016. The company is led by a team of industry veterans with extensive drug discovery and development experience in global pharma and biotech companies, including Pfizer, Amgen, and J&J. From its inception, Phanes has focused on innovative drug discovery and development in immuno-oncology. The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair®, and ATACCbody®. These platforms enable the development of novel biologics that address high unmet medical needs in oncology. PACbody® enables construction of native IgG-like bispecific antibodies (PACbodies) with drug-like properties, produced without any protein fusion steps, significantly reducing CMC risks. SPECpair® enhances the manufacturability of bispecific antibodies so that PACbodies can be produced using the conventional mAb manufacturing process. ATACCbody® is an extension of PACbody® and SPECpair®, enabling reversible modulation of the anti-CD3 activity of T cell engagers, designed to target solid tumors with reduced risk of cytokine release syndrome. As of the latest information, Phanes is conducting three Phase 2 clinical trials with spevatamig, peluntamig, and mavrostobart. Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug and Fast Track designations by the FDA. The company continues to advance its pipeline and technology platforms with the mission to become a major source of innovation in the biopharma industry.

• 2016

  Phanes Therapeutics founded in July 2016.

• Spevatamig and peluntamig granted orphan drug and Fast Track designations by the FDA.

• Three Phase 2 clinical trials ongoing with spevatamig, peluntamig, and mavrostobart.

Clinical-stage biotech focused on innovative drug discovery and development in immuno-oncology, aiming to become a major source of innovation in the biopharma industry.

• spevatamig

  First-in-class bispecific antibody in Phase 2 clinical trials; granted orphan drug and Fast Track designations by the FDA.

• peluntamig

  First-in-class bispecific antibody in Phase 2 clinical trials; granted orphan drug and Fast Track designations by the FDA.

• mavrostobart

  Bispecific antibody in Phase 2 clinical trials.

1. 1Home - Phanes Therapeutics, Incphanesthera.com
2. 2About Us - Phanes Therapeutics, Incphanesthera.com
3. 3Technology - Phanes Therapeutics, Incphanesthera.com
4. 4Scientific Advisory Board - Phanes Therapeutics, Incphanesthera.com
5. 5Phanes Therapeutics, Inc. - Wikidatawikidata.org